Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sichuan Kelun Pharmaceutical Catalyst Calendar
Proactively evaluate Sichuan Kelun Pharmaceutical Co Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Sichuan Kelun Pharmaceutical Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 01 Dec 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 31 Aug 2020 | Phase II Trial Completion | Sichuan Kelun Pharmaceutical Co Ltd | 002422 | KLA-167 | Oncology | Carcinomas; Nasopharyngeal Cancer | Clinical Trial Registry |
| 01 Aug 2020 | Phase IV Trial Initiation | Chizhou People's Hospital; Sichuan Kelun Pharmaceutical Co Ltd | 002422 | zoledronic acid | Musculoskeletal Disorders | Bone Fracture; Osteoporosis | Clinical Trial Registry |
| 01 Feb 2020 | Phase I/II Trial Initiation | KLUS Pharma Inc; Sichuan Kelun Pharmaceutical Co Ltd | 002422 | SKB-264 | Oncology | Adenocarcinoma Of The Gastroesophageal Junction; Breast Cancer; Endometrial Cancer; Epithelial Ovarian Cancer; Gastric Cancer; Head And Neck Cancer Squamous Cell Carcinoma; Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer); Metastatic Transitional (Urothelial) Tract Cancer; Non-Small Cell Lung Cancer; Small-Cell Lung Cancer; Solid Tumor; Transitional Cell Carcinoma (Urothelial Cell Carcinoma); Triple-Negative Breast Cancer (TNBC) | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer